<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00058487</url>
  </required_header>
  <id_info>
    <org_study_id>DFCI-01281</org_study_id>
    <secondary_id>CDR0000298783</secondary_id>
    <secondary_id>CELGENE-2001-P-00170/1</secondary_id>
    <nct_id>NCT00058487</nct_id>
  </id_info>
  <brief_title>Epirubicin and Thalidomide in Treating Patients With Liver Cancer</brief_title>
  <official_title>A Phase II Study Of Epirubicin And Thalidomide In Unresectable Or Metastatic Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop tumor
      cells from dividing so they stop growing or die. Thalidomide may stop the growth of
      hepatocellular (liver) cancer by stopping blood flow to the tumor. Combining epirubicin with
      thalidomide may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combining epirubicin with thalidomide
      in treating patients who have unresectable or metastatic liver cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the antitumor activity of epirubicin and thalidomide in patients with locally
           unresectable or metastatic hepatocellular carcinoma.

        -  Determine the toxic effects of this regimen in these patients.

      OUTLINE: Patients receive epirubicin on days 1, 8, and 15 and thalidomide on days 1-21.
      Courses repeat every 28 days.

      PROJECTED ACCRUAL: A total of 12 patients per year will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antitumor activity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxic effects</measure>
  </primary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of hepatocellular carcinoma

               -  Locally unresectable or metastatic disease

          -  Measurable disease

          -  No clinically apparent CNS metastases

          -  No carcinomatous meningitis

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 12 weeks

        Hematopoietic

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 75,000/mm^3

        Hepatic

          -  SGOT no greater than 5 times upper limit of normal

          -  Bilirubin no greater than 3.0 mg/dL

          -  INR no greater than 1.5*

          -  Albumin at least 2.0 g/dL NOTE: *Not required for patients receiving full
             anticoagulation with warfarin for deep vein thrombosis or pulmonary embolism

        Renal

          -  Creatinine no greater than 2.0 mg/dL

        Cardiovascular

          -  No myocardial infarction within the past 6 months

          -  LVEF normal by echocardiogram or MUGA

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Willing and able to participate in the System for Thalidomide Education and
             Prescribing Safety (STEPS) program

          -  No uncontrolled serious medical or psychiatric illness

          -  No other concurrent uncontrolled malignancy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No more than 1 prior chemotherapy regimen for hepatocellular carcinoma

          -  No prior chemoembolization to the liver

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  More than 2 weeks since prior major surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew X. Zhu, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005 Jun-Jul;10(6):392-8.</citation>
    <PMID>15967833</PMID>
  </results_reference>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

